Analysts Set KALA BIO, Inc. (NASDAQ:KALA) PT at $20.38

Shares of KALA BIO, Inc. (NASDAQ:KALA) have been assigned an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $20.3750.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a research report on Monday, December 29th.

Institutional Trading of KALA BIO

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in KALA BIO in the fourth quarter worth approximately $48,000. XTX Topco Ltd purchased a new stake in shares of KALA BIO in the 2nd quarter valued at $62,000. Jane Street Group LLC purchased a new stake in shares of KALA BIO in the 4th quarter valued at $80,000. Geode Capital Management LLC grew its holdings in shares of KALA BIO by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its position in KALA BIO by 83.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company’s stock worth $1,003,000 after purchasing an additional 818,962 shares during the period. Institutional investors own 24.61% of the company’s stock.

KALA BIO Price Performance

Shares of KALA BIO stock opened at $0.35 on Monday. KALA BIO has a 1 year low of $0.34 and a 1 year high of $20.60. The firm has a market cap of $314.68 million, a PE ratio of -0.06 and a beta of -2.37. The company has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $3.56.

About KALA BIO

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.